![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
KSB AG | TG:KSB | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.00 | -0.75% | 665.00 | 655.00 | 675.00 | 675.00 | 660.00 | 675.00 | 34 | 22:50:02 |
RNS Number:4298P Xenova Group PLC 05 September 2003 Time embargoed until 7.00 a.m. on 5 September 2003 Xenova Group plc Offer for KS Biomedix Holdings Plc Update Not for release, publication or distribution in or into the United States, Canada, Australia or Japan Xenova Group plc ("Xenova"), 5 September 2003 RECOMMENDED OFFER FOR KS BIOMEDIX HOLDINGS PLC ("KS BIOMEDIX") ("THE OFFER") LEVEL OF ACCEPTANCES AND EXTENSION OF OFFER Xenova announces that by 3.00 p.m. on 4 September 2003, being the first closing date of the Offer, valid acceptances of the Offer had been received in respect of 49,610,370 KS Biomedix Shares, representing approximately 76.82 per cent. of the KS Biomedix Issued Share Capital. On 14 August 2003, Xenova announced that it had received irrevocable undertakings to accept the Offer in respect of 24,060,589 KS Biomedix Shares. Valid acceptances have been received in respect of 24,056,589 of the shares subject to these undertakings, representing approximately 37.25 per cent. of the KS Biomedix Issued Share Capital, which are included in the total for valid acceptances. On 14 August 2003, Xenova also announced that it had received an irrevocable undertaking to accept the Offer from a KS Biomedix Director who has interests in securities which are exchangeable into 7,118,897 KS Biomedix Shares (the " Exchangeable Shares"). Pursuant to this undertaking, the KS Biomedix Director has agreed, upon being given notice that the Offer will be declared unconditional in all respects, to exchange, or procure the exchange of, all of the Exchangeable Shares and to accept, or to procure the acceptance of, the Offer in respect of the 7,118,897 KS Biomedix Shares which he or his trustees will be issued upon exchange of the Exchangeable Shares. Accordingly, Xenova has received valid acceptances or has outstanding irrevocable commitments to accept the Offer in respect of a total of 56,729,267 KS Biomedix Shares, representing approximately 87.85 per cent. of the KS Biomedix Issued Share Capital. The Board of Xenova announces that the Offer has been extended until 3.00 p.m. on 11 September 2003. KS Biomedix Shareholders who wish to accept the Offer and have not yet done so should despatch their Form of Acceptance in accordance with the instructions contained therein as soon as possible and, in any event, so as to be received no later than 3.00 p.m. on 11 September 2003. Neither Xenova nor any person deemed to be acting in concert with it held any KS Biomedix Shares or rights over KS Biomedix Shares on 30 July 2003, the last business day immediately prior to the commencement of the Offer Period. Neither Xenova nor any person deemed to be acting in concert with it has acquired or agreed to acquire any KS Biomedix Shares or rights over KS Biomedix Shares since the Offer Period commenced. Terms defined in the Offer Document dated 14 August 2003 have the same meaning in this announcement. Enquiries: Daniel Abrams, Xenova Tel: 01753 706 600 David Rasouly, Nomura Tel: 020 7521 2000 David Yates, Financial Dynamics Tel: 020 7831 3113 Nomura is acting exclusively for Xenova in connection with the Offer and is not advising any other person or treating any other person as its client in relation thereto and will not be responsible to anyone other than Xenova for providing the protections afforded to clients of Nomura or for providing advice in relation to the Offer or the New Xenova Shares. This announcement does not constitute an offer or an invitation to purchase any securities. This announcement does not constitute an offer of securities for sale in the United States and the New Xenova Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended, nor under any laws of any state of the United States, and the relevant clearances have not been and will not be obtained from the relevant authorities in Canada, Australia or Japan. Accordingly, unless an exemption under any applicable laws is available, the New Xenova Shares may not be offered, sold, resold, delivered or transferred directly or indirectly in or into the United States, Canada, Australia or Japan or any other country outside the United Kingdom where such distribution may otherwise lead to a breach of law or other regulatory requirement, or to or for the benefit of US Persons. The Offer referred to in this announcement is not being made, directly or indirectly, in or into, or by use of the mails of or by any means of instrumentality (including, without limitation, facsimile transmissions, telex, telephone or internet) or interstate or foreign commerce of, or any facilities of a securities exchange of, the United States, nor is it being made, directly or indirectly, to or for the benefit of US Persons, nor is it being made, directly or indirectly, in or into Canada, Australia, or Japan unless an exemption under any applicable laws is available. This announcement is not being, and it must not be, mailed or otherwise forwarded, distributed or sent in, or into the United States, Canada, Australia or Japan and doing so may render invalid any purported acceptance of the Offer. This information is provided by RNS The company news service from the London Stock Exchange END OUPUUURCBUPWGRC
1 Year KSB Chart |
1 Month KSB Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions